First Continuous Biologics Manufacturing Facility Promises to Disrupt the mAb Manufacturing Cost

Enzene Biosciences Ltd, Pune (India) formally opened its first fully connected continuous Biologics manufacturing facility in Pune, India last week ( November 7, 2019). The state-of-the-art manufacturing plant has a significantly smaller footprint than the conventional manufacturing facilities. It was built in half the time that conventional biologics manufacturing plants would take to complete.


Enzene is an innovation driven biotech company and a subsidiary of Alkem Laboratories Ltd (the 5th largest pharmaceutical company in India as per IQVIA MAT September 2019). Enzene’s focus lies in producing biosimilars, phytopharmaceuticals and synthetic peptides while venturing into novel biologics.


Enzene is amongst the first movers in end-to-end connected bio manufacturing to have set up a fully automated continuous cGMP compliant manufacturing plant for mAb production. It is capable of delivering higher production compared to a traditional manufatcuring  plant and, will also enable the company, as well its potential clients, to rapidly move their early/pre-clinical assets to the later stage of development or to the commercial stage.


Enzene’s Unit I – Chakan


The company’s mission is to deliver cost effective biosimilars by developing disruptive technologies, advanced analytics and state-of-the-art manufacturing facility. Mr. Sandeep Singh, the MD of Alkem Laboratories Ltd said “some of the world’s biggest drugs are biologics and Alkem laboratories Ltd. always aspired to enter the arena of biologics. With that intent, we have invested significantly into this space. Our new biologics manufacturing plant endorses our commitment to expand into the space of biotech innovations.”


Enzene aims to broaden its footprint for innovative technologies through strategic global alliances and has taken first steps towards it by procuring its first European client project for cGMP manufacturing of clinical material and create minimal solid waste and carbon emission.


Full-Time Director and CSO at Enzene, Dr. Himanshu Gadgil commented “high cost of manufacturing is one of the major barriers for the entry of biologics into the clinical stage of development. Enzene wishes to disrupt this cost barrier through the launch of their innovative manufacturing plant.”


Source: Enzene Biosciences Ltd